Assembly Biosciences (ASMB) to Announce Quarterly Earnings on Wednesday

Assembly Biosciences (NASDAQ:ASMB) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Assembly Biosciences to announce earnings of ($0.70) per share and revenue of $8.5990 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The business had revenue of $8.21 million for the quarter, compared to analysts’ expectations of $9.27 million. On average, analysts expect Assembly Biosciences to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Assembly Biosciences Trading Up 1.0%

Shares of ASMB opened at $25.36 on Tuesday. The company’s fifty day simple moving average is $25.78 and its 200-day simple moving average is $27.43. The company has a market cap of $403.05 million, a P/E ratio of -230.52 and a beta of 1.08. Assembly Biosciences has a twelve month low of $17.98 and a twelve month high of $39.71.

Institutional Investors Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Informed Momentum Co LLC grew its holdings in Assembly Biosciences by 1.6% during the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock worth $1,004,000 after acquiring an additional 451 shares in the last quarter. ADAR1 Capital Management LLC raised its holdings in shares of Assembly Biosciences by 4.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 800 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Assembly Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after purchasing an additional 1,212 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the period. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Assembly Biosciences in the 4th quarter worth approximately $228,000. 19.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Guggenheim reiterated a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a report on Thursday, May 28th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday, May 4th. Mizuho set a $45.00 target price on Assembly Biosciences and gave the company an “outperform” rating in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $44.00.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.